San Francisco, CA · Founded 2016 · Healthcare AI
Before you finish your CT scan. Before the radiologist files the report. Before anyone fills out a single form. Viz.ai already sent the alert.
The images are processing. Somewhere else in the same hospital - or across town, or in another state - a neurovascular specialist is eating lunch, reviewing notes, finishing a call. In the old system, connecting those two people fast enough was a matter of luck, protocol compliance, and someone remembering to page the right person.
Viz.ai removed the luck variable.
The company's AI platform sits inside the radiology pipeline at more than 2,000 U.S. hospitals. When imaging data comes in, Viz.ai's algorithms analyze it in real time - looking for signs of large vessel occlusion, intracranial hemorrhage, cerebral aneurysm, pulmonary embolism, hypertrophic cardiomyopathy, and a growing list of other time-sensitive conditions. If it finds something, it sends an alert. Not an email. Not a fax. A direct notification to the specialist's phone, within seconds of the scan completing.
Ninety percent of those alerts are reviewed within five minutes.
"Time is brain. Every minute of delayed stroke treatment costs roughly two million neurons. Viz.ai exists to eliminate the minutes that don't need to exist."
Company core value: "Time is Brain"The platform covers roughly two-thirds of the American population. It supports 70,000+ clinicians across specialties - neurologists, cardiologists, radiologists, trauma surgeons, pulmonologists. It has 50+ FDA-cleared algorithms, a growing life sciences division that partners with 14+ pharmaceutical companies, and in 2025 it hit profitability in its core healthcare business. The company did not stumble into any of this. It was designed around a specific, solvable problem.
Dr. Chris Mansi was a Cambridge-trained neurosurgeon. He had done everything right. His patient underwent successful brain surgery, and what followed should have been recovery. Instead, Mansi watched the coordination system fail in slow motion - the wrong people were notified too late, the right treatment came after the window had closed. The surgery was a success. The patient died.
Mansi enrolled in Stanford's Biodesign Innovation program to figure out how to fix the problem systematically. He met Dr. David Golan, a machine learning researcher who had his own personal encounter with neurological illness. They compared notes. The failure wasn't medical - it was informational. Imaging systems, hospital communication tools, and specialist workflows weren't connected in any meaningful way. The data existed. Nobody moved it fast enough.
In 2016, they founded Viz.ai to build the connective tissue that hospitals didn't have.
Mansi and Golan found Viz.ai after Stanford Biodesign. First investors: DHVC, Innovation Endeavors, Seedcamp.
Viz LVO becomes the first AI algorithm to receive De Novo FDA authorization for stroke detection in CT angiography - creating an entirely new regulatory category. Kleiner Perkins + GV invest $21M Series A.
Greenoaks Capital leads the round, marking their first investment in Viz.ai. Platform scaling across U.S. hospital networks.
Scale Venture Partners and Insight Partners lead. Platform now covering significant portion of U.S. hospital networks with multi-specialty expansion.
Tiger Global leads. Valuation hits $1.2B. First company to receive CMS reimbursement for AI. Platform reaches majority of top 50 U.S. health systems.
Viz HCM becomes first-ever De Novo authorized cardiovascular ML notification software. $40M Series E closes. Goldman Sachs names Mansi one of Most Exceptional Entrepreneurs.
2,000 hospitals. 70,000+ providers. Third consecutive Edison Award. TIME Magazine Top Health Companies. Profitable healthcare business. Doubled life sciences revenue in 18 months.
First agentic AI platform for health systems - hospitals build their own AI care pathways using plain English. Salesforce and Alnylam partnerships announced.
Viz.ai's product architecture is deliberately unglamorous. It connects to a hospital's existing imaging infrastructure, reads incoming scans as they come off the machine, applies FDA-cleared deep learning models, and routes the findings to the right clinician via the platform's HIPAA-compliant messaging system. There is no rip-and-replace. No months-long EHR migration. The value proposition is immediate: plug in, and the algorithm starts working.
The suite has grown well beyond stroke. Viz One - the core platform - now spans neurovascular, cardiovascular, vascular, trauma, radiology, pulmonary, and oncology. Each condition has its own workflow, built around clinical evidence and validated in peer-reviewed literature. More than 120 clinical publications support the platform's claims.
Large vessel occlusion, intracranial hemorrhage, cerebral aneurysm, subdural hemorrhage - detected in CT within seconds of scan completion.
Hypertrophic cardiomyopathy detection and management. First De Novo FDA-cleared cardiovascular ML notification software.
Pulmonary embolism detection with automated RV/LV ratio analysis. FDA cleared, clinically validated.
Aortic aneurysm detection and vascular workflow coordination - including the first FDA-cleared AI for abdominal aortic aneurysm.
AI triage and care coordination for trauma centers. Faster activation, faster treatment, fewer delays at handoff.
AI-powered oncology workflows developed in partnership with Novartis. Patient identification, care pathway coordination.
Launched March 2026. Health systems build their own AI care pathways using plain language. Clinical guidelines become executable workflows.
AI-powered patient identification and real-world evidence for pharma and medical device partners. 14+ pharmaceutical partnerships active.
Viz.ai Platform - Key Clinical and Operational Metrics
Sources: Viz.ai clinical publications, company disclosures. Bar widths are normalized for visual comparison.
The healthcare AI market has been littered with tools that looked good in demos and disappeared in deployment. Viz.ai has made clinical validation a core business function. The company has published over 120 peer-reviewed studies and conference abstracts. The International Stroke Conference has seen six Viz Neuro Suite studies in a single year. This is the kind of evidence base that makes hospital procurement committees say yes and keeps them there.
The customers are not small community hospitals testing a pilot. Viz.ai's network includes the majority of the 50 largest U.S. health systems. They renewed. They expanded. The platform now covers 230 million people - not because of marketing, but because the clinical teams using it kept pushing for broader deployment.
"The company achieved profitability in its healthcare business in 2025, while simultaneously doubling its life sciences revenue in 18 months. That is not a common combination."
Viz.ai 2025 Year-End ResultsThe life sciences pivot is equally deliberate. When a pharmaceutical company develops a drug for a rare cardiac condition, finding eligible patients is the hard part. Viz.ai sits inside the imaging workflow of 2,000 hospitals. Its algorithms already flag the patients who meet treatment criteria. Fourteen pharmaceutical partnerships - with names including Novartis, Bristol Myers Squibb, Regeneron, Sanofi, and Alnylam - use this infrastructure to accelerate clinical trials and commercial patient activation. It is a second business model running on the same platform, and it is growing faster.
| Round | Date | Amount | Lead Investors |
|---|---|---|---|
| Seed | Sept 2016 | $7.5M | DHVC, Innovation Endeavors, Seedcamp |
| Series A | 2018 | $21M | Kleiner Perkins, GV (Google Ventures) |
| Series B | Oct 2019 | $50M | Greenoaks Capital |
| Series C | Mar 2021 | $71M | Scale Venture Partners, Insight Partners |
| Series D | Apr 2022 | $100M | Tiger Global, Insight Partners |
| Series E | Mar 2023 | $40M | Existing investors |
$1.2B valuation as of Series D (April 2022). Total funding: $291M+.
Machine learning innovation in healthcare AI - 2023, 2024, and 2025.
Black Book Research - two consecutive years for AI-Powered Acute Care & Clinical Decision Support.
First company to receive CMS reimbursement for an AI algorithm.
February 2018 - FDA De Novo authorization for AI-based LVO stroke detection. Created a new regulatory category.
Named to TIME Magazine's World's Top Health Companies 2025.
CEO Chris Mansi recognized at Goldman Sachs Builders and Innovators Summit 2023.
Healthcare AI is crowded with promises. What separates Viz.ai is that it chose to compete on evidence - clinical validation, regulatory clearance, real-world performance data - rather than demos and press releases. That strategy is slow at first and then compounding. One FDA clearance becomes fifty. One hospital becomes two thousand. One pharmaceutical partnership becomes fourteen. One clinical publication becomes one hundred and twenty.
The next chapter is agentic AI. Viz Agent Studio, launched in March 2026, lets hospitals build their own AI care pathways using plain language instructions. Type in a clinical guideline. The platform converts it into a workflow, deploys it across the enterprise, and measures its performance. The implication is significant: Viz.ai stops being a vendor and becomes an infrastructure layer that hospitals build on top of.
"Two thousand hospitals. Ninety percent alert click-through. The AI is doing its job. Now it's teaching hospitals to build their own."
Viz Agent Studio launch, March 2026Return to that scanner room at the beginning. A patient is being imaged. The stroke is there in the data, visible if you know where to look and can process the information fast enough. Viz.ai is looking. The neurovascular specialist's phone has already buzzed. The treatment window - the narrow margin where intervention saves function, saves life - is still open.
That is the problem Dr. Chris Mansi watched kill his patient in 2016. That is the problem that Viz.ai solved in 2,000 hospitals, for two-thirds of the American population, 70,000 healthcare providers at a time. The surgery still has to succeed. But the coordination failure that follows it - the one that costs neurons, function, and sometimes lives - that one has a fix now.
The company's name comes from "visualization" - the idea that making invisible emergencies visible to the right clinician is the entire job.
Viz LVO's 2018 FDA De Novo authorization didn't just clear a product - it created a new regulatory category that didn't exist before, one that future AI stroke tools would apply under.
90% of Viz.ai alerts are reviewed within five minutes. For a stroke, those five minutes can be the difference between walking out of the hospital and not.
The platform covers roughly two-thirds of the American population - not through marketing, but because health systems kept expanding their deployments after seeing clinical results.
Co-founder David Golan had his own personal neurological event before founding the company. This is not a story about founders who identified a market. It's a story about founders who lived the problem.
The company operates with engineering teams across five continents. The Israeli R&D office, led by VP Oded Cohen, handles a significant portion of algorithm development.